Six states with laws enabling the importation of prescription drugs from Canada – Vermont, Florida, Maine, Colorado, New Mexico, and New Hampshire – are awaiting publication of federal rules currently under review by the Office of Management and Budget. They are eager to see if the final rules address key concerns submitted by the National […]
Author Archive for: jennifer-reck
About Jennifer Reck
Jennifer Reck is project director of NASHP’s Center for State Prescription Drug Pricing. The center works with states to develop model policies to address drug prices, tracks legislation and implementation, and provides technical assistance. Since joining NASHP in 2015, she has designed and implemented technical assistance for state learning collaboratives to advance evidence-based policymaking and alternative payment models. She has also directed evaluation teams analyzing delivery system and payment reforms, including State Innovation Models, and led efforts to disseminate findings from a federal initiative to advance evidence-based preventive care.
Prior to joining NASHP in 2015, Jennifer was Maine Medical Association’s (MMA) director of grants management, where she engaged physicians in payment reform as well as outreach and advocacy efforts to implement the Affordable Care Act. She also directed the MMA’s academic detailing program – the Maine Independent Clinical Information Service – an educational outreach program to promote evidence-based primary care. She has also worked as a policy analyst at Prescription Policy Choices, providing states with policy models and technical assistance to address clinical and cost concerns related to prescription drugs, and as a publishing editor at Elsevier Science, managing its portfolio of health policy journals.
She received her master’s degree from Cornell University in Science and Technology Studies and her bachelor’s degree in the history and philosophy of science from Bard College.
Entries by Jennifer Reck
Unpredictable and unrelenting drug price increases drive up health insurance premiums and challenge states’ public purchasers as they weigh escalating costs against balanced budget requirements. The National Academy for State Health Policy’s (NASHP) newest model law, an Act to Protect Consumers from Unsupported Price Increases on Prescription Drugs, levies hefty fines on manufacturers that impose […]
Getting a grip on pharmaceutical manufacturers’ pricing strategies is a 2020 priority for the National Academy for State Health Policy (NASHP), but how drugs are marketed also significantly impacts spending on drugs. In 2016, pharmaceutical companies spent $6 billion on direct-to-consumer advertising, but a whopping $20.3 billion to market their brand name drugs to health […]
As the nation grapples with the pandemic, new research has identified dexamethasone, a low-cost generic drug, as a promising treatment for certain COVID-19 patients. But consumers worry – will its cost remain low? Will new treatments be affordable?
The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule with provisions designed to advance value-based purchasing (VBP) arrangements with drug manufacturers. Comments about the proposal are due July 20, 2020.
Removing wasteful drugs from formularies and replacing them with drugs that offer the same benefits at a lower cost, helps state employee health plans and other public purchasers reduce spending without sacrificing value – a critical strategy for savings as states face tremendous budget pressures.
States are experiencing a huge rise in the number of people without health insurance in the wake of mass layoffs resulting from the COVID-19 pandemic and are seeking strategies to protect them from high prescription drug prices. The uninsured are sometimes the only consumers left paying the full list price for a drug, while the […]
Last week, a California Court of Appeal lifted an injunction that prevented the state from sharing drug manufacturers’ advance notice of drug price increases. The ruling was a win for states working to advance drug price transparency in the face of manufacturers’ sometimes overly-broad claims of trade secret protection for their prices.
More than 50 major health systems, including hospitals in every state, have joined forces to create Civica Rx, a nonprofit drug manufacturer that produces affordable, sustainable supplies of certain generic medications – a mission made more critical than ever by generic shortages related to the COVID-19 pandemic.
Absent sufficient evidence from clinical trials that proves a variety of drugs are effective against COVID-19, many states are providing guidance to limit their use and have begun monitoring them for price increases and shortages. Building on experience from states’ drug price transparency laws, policymakers now have tools to track these drug costs and identify […]